Uveitis is a general term describing a group of inflammatory diseases that produces swelling and destroys eye tissues. These diseases can slightly reduce vision or lead to severe vision loss.

The term “uveitis” is used because the diseases often affect a part of the eye called the uvea. Nevertheless, uveitis is not limited to the uvea. These diseases also affect the lens, retina, optic nerve, and vitreous, producing reduced vision or blindness.
Uveitis may be caused by problems or diseases occurring in the eye or it can be part of an inflammatory disease affecting other parts of the body.
It can happen at all ages and primarily affects people between 20 ñ 60 years old. Uveitis can last for a short (acute) or a long (chronic) time. The severest forms of uveitis reoccur many times.- NIH

Clearside announces positive Phase II results in win for back-of-the-eye drug delivery

By Varun Saxena
Most drugs are injected into the eye’s intravitreal chamber, but Alpharetta, GA’s Clearside believes that injection into the suprachoroidal space (located between the sclera and choroid) avoids some of the risks of intravitreal delivery into the vitreous chamber including vitreous hemorrhage, retinal detachment and the proliferation of visual “floaters”–while still enabling access to posterior segment ocular tissue.
Fresh off a $20 million Series C financing, the company announced strong results from its Phase II clinical trial of its proprietary form of triamcinolone acetonide (CLS-TA) to treat macular edema associated with noninfectious uveitis.
Uveitis causes about 10% of the incidence of blindness in the U.S. and affects about 350,000 Americans.
In the 8-week, 22-patient trial, administration of CLS-TA “resulted in a statistically significant mean change from baseline in central subfield thickness at eight weeks after one single treatment, which was the primary endpoint,” according to a company release.
The secondary endpoint, mean increase from baseline in best-corrected visual acuity, was also met……
Read more: http://www.fiercedrugdelivery.com/story/clearside-announces-positive-phase-ii-results-win-back-eye-drug-delivery/2016-01-05
Source: Fierce Drug Delivery